Probiotics shifted testosterone, insulin and weight in women with PCOS

Polycystic ovary syndrome is one of the most common hormonal conditions in women, and its reach extends well beyond the ovaries. Many women with PCOS carry higher insulin and testosterone levels, along with unfavourable blood fats and a tendency to gain weight, which together raise long-term metabolic risk. Interest has grown in whether the gut can be recruited to help, since probiotic and synbiotic supplements are cheap, widely available and low risk. Individual trials have been small and scattered across many different outcomes, so pooling them is the only way to find out whether there is a real signal underneath.

The researchers swept four major research databases from their start to March 19, 2026, looking for randomised controlled trials of probiotic or synbiotic supplementation in women with PCOS. Eleven trials met the bar, covering 780 participants between them. Each trial's quality was assessed with a standard risk of bias tool, and the certainty of the evidence was graded for every outcome. Results were then pooled across insulin resistance, reproductive hormones, blood fats, inflammation, body measurements and markers of oxidative stress. The review was registered in advance, which guards against cherry-picking outcomes after seeing the data.

Supplementation lowered fasting insulin, total testosterone, triglycerides and LDL cholesterol, and shaved a little off BMI and body weight, while HDL cholesterol and total antioxidant capacity rose. The certainty of the evidence was rated high for the testosterone, triglyceride, LDL, HDL, BMI and body weight findings, moderate for fasting insulin, and low for antioxidant capacity. Just as notable is what did not move: fasting glucose, the standard insulin resistance indices, several reproductive hormones including FSH, LH, SHBG and DHEAS, total cholesterol, the inflammation marker C-reactive protein, and waist and hip circumference all showed no significant change. The single prebiotic trial contributed only to the weight-related outcomes.

This pooling strengthens the case that the gut is a legitimate target in PCOS rather than a fad, with several outcomes now backed by high-certainty evidence. At the same time it complicates the simplest story, because the headline measures of blood sugar control did not improve even though fasting insulin fell. The picture for prebiotics on their own is nearly blank, resting on a single trial. Open questions remain around which strains, which doses and how long supplementation needs to run, none of which this analysis could settle.

For women with PCOS, this is a reason to take probiotic and synbiotic supplements seriously as a supporting act, since pooled trial evidence now links them to real movement in testosterone, cholesterol and weight. The honest framing is a nudge, not a fix: the changes were modest and blood glucose control did not improve. Anyone managing PCOS alongside a clinician has grounds to raise the topic rather than to swap out existing care. For readers without PCOS, nothing here speaks to whether the same supplements would do anything at all.